메뉴 건너뛰기




Volumn 5, Issue 8, 2013, Pages 859-868

Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines

Author keywords

acute myeloid leukemia; blebs; dendritic cell vaccination; DRibbles; immunotherapy; leukemia initiating cell; whole cell vaccine

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MELANOMA ANTIGEN 3; PICIBANIL; TUMOR CELL VACCINE;

EID: 84881273965     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.76     Document Type: Review
Times cited : (8)

References (80)
  • 1
    • 0027941369 scopus 로고
    • Intensive postremission chemotherapy in adults with acute myeloid leukemia
    • Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331(14), 896-903 (1994
    • (1994) N. Engl. J. Med , vol.331 , Issue.14 , pp. 896-903
    • Mayer, R.J.1    Davis, R.B.2    Schiffer, C.A.3
  • 2
    • 70349451999 scopus 로고    scopus 로고
    • High-dose daunorubicin in older patients with acute myeloid leukemia
    • Löwenberg B, Ossenkoppele GJ, van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361(13), 1235-1248 (2009
    • (2009) N. Engl. J. Med , vol.361 , Issue.13 , pp. 1235-1248
    • Löwenberg, B.1    Ossenkoppele, G.J.2    Van Putten, W.3
  • 3
    • 84872087060 scopus 로고    scopus 로고
    • Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
    • Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121(1), 26-28 (2013
    • (2013) Blood , vol.121 , Issue.1 , pp. 26-28
    • Löwenberg, B.1
  • 4
    • 84873335475 scopus 로고    scopus 로고
    • Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older
    • Gardin C, Chevret S, Pautas C et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J. Clin. Oncol. 31(3), 321-327 (2013
    • (2013) J. Clin. Oncol , vol.31 , Issue.3 , pp. 321-327
    • Gardin, C.1    Chevret, S.2    Pautas, C.3
  • 5
    • 0025100777 scopus 로고
    • Graft-versus-leukemia reactions after bone marrow transplantation
    • Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3), 555-562 (1990
    • (1990) Blood , vol.75 , Issue.3 , pp. 555-562
    • Horowitz, M.M.1    Gale, R.P.2    Sondel, P.M.3
  • 6
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
    • (2010) N. Engl. J. Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 7
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD 1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD 1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
    • (2012) N. Engl. J. Med , vol.366 , Issue.26 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 8
    • 69049089548 scopus 로고    scopus 로고
    • The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research
    • Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009
    • (2009) Clin. Cancer Res , vol.15 , Issue.17 , pp. 5323-5337
    • Cheever, M.A.1    Allison, J.P.2    Ferris, A.S.3
  • 9
    • 84867685827 scopus 로고    scopus 로고
    • Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
    • Landsberg J, Kohlmeyer J, Renn M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490(7420), 412-416 (2012
    • (2012) Nature , vol.490 , Issue.7420 , pp. 412-416
    • Landsberg, J.1    Kohlmeyer, J.2    Renn, M.3
  • 10
    • 84860436621 scopus 로고    scopus 로고
    • Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A Phase 1 dose-escalation trial
    • van den Eertwegh AJM, Versluis J, van den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A Phase 1 dose-escalation trial. Lancet Oncol. 13(5), 509-517 (2012
    • (2012) Lancet Oncol , vol.13 , Issue.5 , pp. 509-517
    • Van Den Eertwegh, A.J.M.1    Versluis, J.2    Van Den Berg, H.P.3
  • 11
    • 0034614886 scopus 로고    scopus 로고
    • The induction of tolerance by dendritic cells that have captured apoptotic cells
    • Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191(3), 411-416 (2000
    • (2000) J. Exp. Med , vol.191 , Issue.3 , pp. 411-416
    • Steinman, R.M.1    Turley, S.2    Mellman, I.3    Inaba, K.4
  • 12
    • 77956255766 scopus 로고    scopus 로고
    • Find-me and eat-me signals in apoptotic cell clearance: Progress and conundrums
    • Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: Progress and conundrums. J. Exp. Med. 207(9), 1807-1817 (2010
    • (2010) J. Exp. Med , vol.207 , Issue.9 , pp. 1807-1817
    • Ravichandran, K.S.1
  • 13
    • 80755180853 scopus 로고    scopus 로고
    • Beginnings of a good apoptotic meal: The find-me and eat-me signaling pathways
    • Ravichandran KS. Beginnings of a good apoptotic meal: The find-me and eat-me signaling pathways. Immunity 35(4), 445-455 (2011
    • (2011) Immunity , vol.35 , Issue.4 , pp. 445-455
    • Ravichandran, K.S.1
  • 14
    • 77956941695 scopus 로고    scopus 로고
    • Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes
    • Meesmann HM, Fehr EM, Kierschke S et al. Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes. J. Cell Sci. 123(Pt 19), 3347-3356 (2010
    • (2010) J. Cell Sci , vol.123 , Issue.PART 19 , pp. 3347-3356
    • Meesmann, H.M.1    Fehr, E.M.2    Kierschke, S.3
  • 15
    • 3543053363 scopus 로고    scopus 로고
    • Immature dendritic cells phagocytose apoptotic cells via avb5 CD36 and cross-present antigens to cytotoxic T lymphocytes
    • Albert ML, Pearce SFA, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via avb5 CD36 and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188(7), 1359-1368 (1998
    • (1998) J. Exp. Med , vol.188 , Issue.7 , pp. 1359-1368
    • Albert, M.L.1    Pearce, S.F.A.2    Francisco, L.M.3
  • 16
    • 77949881623 scopus 로고    scopus 로고
    • LOX-1 as a natural IFN a-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells
    • Parlato S, Romagnoli G, Spadaro F et al. LOX-1 as a natural IFN a-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 115(8), 1554-1563 (2010
    • (2010) Blood , vol.115 , Issue.8 , pp. 1554-1563
    • Parlato, S.1    Romagnoli, G.2    Spadaro, F.3
  • 17
    • 0034091785 scopus 로고    scopus 로고
    • Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
    • Russo V, Tanzarella S, Dalerba P et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc. Natl Acad. Sci. USA 97(5), 2185-2190 (2000
    • (2000) Proc. Natl Acad. Sci. USA , vol.97 , Issue.5 , pp. 2185-2190
    • Russo, V.1    Tanzarella, S.2    Dalerba, P.3
  • 18
    • 0033565513 scopus 로고    scopus 로고
    • Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines
    • Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Grégoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res. 59(14), 3329-3332 (1999
    • (1999) Cancer Res , vol.59 , Issue.14 , pp. 3329-3332
    • Henry, F.1    Boisteau, O.2    Bretaudeau, L.3    Lieubeau, B.4    Meflah, K.5    Grégoire, M.6
  • 19
    • 0031798137 scopus 로고    scopus 로고
    • Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
    • Inaba K, Turley S, Yamaide F et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188(11), 2163-2173 (1998
    • (1998) J. Exp. Med , vol.188 , Issue.11 , pp. 2163-2173
    • Inaba, K.1    Turley, S.2    Yamaide, F.3
  • 20
    • 1542373657 scopus 로고    scopus 로고
    • Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis
    • Wilson NS, El-Sukkari D, Villadangos JA. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 103(6), 2187-2195 (2004
    • (2004) Blood , vol.103 , Issue.6 , pp. 2187-2195
    • Wilson, N.S.1    El-Sukkari, D.2    Villadangos, J.A.3
  • 21
    • 77953417284 scopus 로고    scopus 로고
    • Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia
    • van den Ancker W, van Luijn MM, Westers TM et al. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy 2(1), 69-83 (2010
    • (2010) Immunotherapy , vol.2 , Issue.1 , pp. 69-83
    • Van Den Ancker, W.1    Van Luijn, M.M.2    Westers, T.M.3
  • 22
    • 0037268105 scopus 로고    scopus 로고
    • Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia
    • Westers TM, Stam AG, Scheper RJ et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cell 52(1), 17-27 (2003
    • (2003) Cell , vol.52 , Issue.1 , pp. 17-27
    • Westers, T.M.1    Stam, A.G.2    Scheper, R.J.3
  • 23
    • 78649479185 scopus 로고    scopus 로고
    • Sirna silencing of PD L1 and PD L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells
    • Hobo W, Maas F, Adisty N et al. siRNA silencing of PD L1 and PD L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood 116(22), 4501-4511 (2010
    • (2010) Blood , vol.116 , Issue.22 , pp. 4501-4511
    • Hobo, W.1    Maas, F.2    Adisty, N.3
  • 24
    • 34848827168 scopus 로고    scopus 로고
    • Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-Antigen positive tumors
    • Tamir A, Basagila E, Kagahzian A et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-Antigen positive tumors. Cell 56(12), 2003-2016 (2007
    • (2007) Cell , vol.56 , Issue.12 , pp. 2003-2016
    • Tamir, A.1    Basagila, E.2    Kagahzian, A.3
  • 25
    • 73349131696 scopus 로고    scopus 로고
    • Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients
    • Toh HC, Wang WW, Chia WK et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin. Cancer Res. 15(24), 7726-7736 (2009
    • (2009) Clin. Cancer Res , vol.15 , Issue.24 , pp. 7726-7736
    • Toh, H.C.1    Wang, W.W.2    Chia, W.K.3
  • 26
    • 77958575663 scopus 로고    scopus 로고
    • Harnessing naturally occurring tumor immunity: A clinical vaccine trial in prostate cancer
    • Frank MO, Kaufman J, Tian S et al. Harnessing naturally occurring tumor immunity: A clinical vaccine trial in prostate cancer. PLoS ONE 5(9), e12367 (2010
    • (2010) PLoS ONE , vol.5 , Issue.9
    • Frank, M.O.1    Kaufman, J.2    Tian, S.3
  • 27
    • 79952635146 scopus 로고    scopus 로고
    • Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia
    • Kitawaki T, Kadowaki N, Fukunaga K et al. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp. Hematol. 39(4), 424-433 e2 (2011
    • (2011) Exp. Hematol , vol.39 , Issue.4
    • Kitawaki, T.1    Kadowaki, N.2    Fukunaga, K.3
  • 28
    • 43749119376 scopus 로고    scopus 로고
    • Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response
    • Hus I, Schmitt M, Tabarkiewicz J et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 22(5), 1007-1017 (2008
    • (2008) Leukemia , vol.22 , Issue.5 , pp. 1007-1017
    • Hus, I.1    Schmitt, M.2    Tabarkiewicz, J.3
  • 29
    • 0018970399 scopus 로고
    • Results of randomized trials of immunotherapy for acute leukemia
    • Vogler W. Results of randomized trials of immunotherapy for acute leukemia. Cell 9(1-2), 15-21 (1980
    • (1980) Cell , vol.9 , Issue.1-2 , pp. 15-21
    • Vogler, W.1
  • 30
    • 33846057130 scopus 로고    scopus 로고
    • Calreticulin exposure dictates the immunogenicity of cancer cell death
    • Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13(1), 54-61 (2007
    • (2007) Nat. Med , vol.13 , Issue.1 , pp. 54-61
    • Obeid, M.1    Tesniere, A.2    Ghiringhelli, F.3
  • 32
    • 37349051718 scopus 로고    scopus 로고
    • Molecular characteristics of immunogenic cancer cell death
    • Tesniere A, Panaretakis T, Kepp O et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15(1), 3-12 (2008
    • (2008) Cell Death Differ , vol.15 , Issue.1 , pp. 3-12
    • Tesniere, A.1    Panaretakis, T.2    Kepp, O.3
  • 33
    • 0032779055 scopus 로고    scopus 로고
    • Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity
    • Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood 94(12), 4263-4273 (1999
    • (1999) Blood , vol.94 , Issue.12 , pp. 4263-4273
    • Dunussi-Joannopoulos, K.1    Runyon, K.2    Erickson, J.3    Schaub, R.G.4    Hawley, R.G.5    Leonard, J.P.6
  • 34
    • 34447123763 scopus 로고    scopus 로고
    • Granulocyte macrophage colony-stimulating factor -secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
    • Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor -secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13(13), 3883-3891 (2007
    • (2007) Clin. Cancer Res , vol.13 , Issue.13 , pp. 3883-3891
    • Small, E.J.1    Sacks, N.2    Nemunaitis, J.3
  • 35
    • 0034689496 scopus 로고    scopus 로고
    • Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line
    • Osanto S, Schiphorst PP, Weijl NI et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. 11(5), 739-750 (2000
    • (2000) Hum. Gene Ther , vol.11 , Issue.5 , pp. 739-750
    • Osanto, S.1    Schiphorst, P.P.2    Weijl, N.I.3
  • 36
    • 0036181209 scopus 로고    scopus 로고
    • Vaccination of stage IV patients with allogeneic IL 4-or IL 2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells
    • Maio M, Fonsatti E, Lamaj E et al. Vaccination of stage IV patients with allogeneic IL 4-or IL 2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cell 51(1), 9-14 (2002
    • (2002) Cell , vol.51 , Issue.1 , pp. 9-14
    • Maio, M.1    Fonsatti, E.2    Lamaj, E.3
  • 37
    • 0033544933 scopus 로고    scopus 로고
    • Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
    • Arienti F, Belli F, Napolitano F et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 10, 2907-2916 (1999
    • (1999) Hum. Gene Ther , vol.10 , pp. 2907-2916
    • Arienti, F.1    Belli, F.2    Napolitano, F.3
  • 38
    • 0030820018 scopus 로고    scopus 로고
    • A Phase I clinical trial of immunotherapy with interferon-g gene-modified autologous melanoma cells: Monitoring the humoral immune response
    • Abdel-Wahab Z, Weltz C, Hester D et al. A Phase I clinical trial of immunotherapy with interferon-g gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 80(3), 401-412 (1997
    • (1997) Cancer , vol.80 , Issue.3 , pp. 401-412
    • Abdel-Wahab, Z.1    Weltz, C.2    Hester, D.3
  • 39
    • 0031895957 scopus 로고    scopus 로고
    • Vaccination with IL 12 gene-modified autologous melanoma cells: Preclinical results and a first clinical Phase I study
    • Sun Y, Jurgovsky K, Möller P et al. Vaccination with IL 12 gene-modified autologous melanoma cells: Preclinical results and a first clinical Phase I study. Gene Ther. 5(4), 481-490 (1998
    • (1998) Gene Ther , vol.5 , Issue.4 , pp. 481-490
    • Sun, Y.1    Jurgovsky, K.2    Möller, P.3
  • 40
    • 33845721818 scopus 로고    scopus 로고
    • GM CSF gene-modifed cancer cell immunotherapies: Of mice and men
    • Hege KM, Jooss K, Pardoll D. GM CSF gene-modifed cancer cell immunotherapies: Of mice and men. Int. Rev. Immunol. 25(5-6), 321-352 (2006
    • (2006) Int. Rev. Immunol , vol.25 , Issue.5-6 , pp. 321-352
    • Hege, K.M.1    Jooss, K.2    Pardoll, D.3
  • 41
    • 70349446800 scopus 로고    scopus 로고
    • Biologic activity of irradiated, autologous, GM CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
    • Ho VT, Vanneman M, Kim H et al. Biologic activity of irradiated, autologous, GM CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc. Natl Acad. Sci. USA 106(37), 15825-15830 (2009
    • (2009) Proc. Natl Acad. Sci. USA , vol.106 , Issue.37 , pp. 15825-15830
    • Ho, V.T.1    Vanneman, M.2    Kim, H.3
  • 42
    • 70349242210 scopus 로고    scopus 로고
    • Granulocyte-macrophage colony-stimulating factor (GM CSF secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
    • Borrello IM, Levitsky HI, Stock W et al. Granulocyte-macrophage colony-stimulating factor (GM CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 114(9), 1736-1745 (2009
    • (2009) Blood , vol.114 , Issue.9 , pp. 1736-1745
    • Borrello, I.M.1    Levitsky, H.I.2    Stock, W.3
  • 43
    • 18144372419 scopus 로고    scopus 로고
    • Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst Phase I clinical trial
    • Escudier B, Dorval T, Chaput N et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst Phase I clinical trial. J. Transl. Med. 3(1), 10 (2005
    • (2005) J. Transl. Med , vol.3 , Issue.1 , pp. 10
    • Escudier, B.1    Dorval, T.2    Chaput, N.3
  • 44
    • 52049102433 scopus 로고    scopus 로고
    • Efficient cross-presentation depends on autophagy in tumor cells
    • Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 68(17), 6889-6895 (2008
    • (2008) Cancer Res , vol.68 , Issue.17 , pp. 6889-6895
    • Li, Y.1    Wang, L.X.2    Yang, G.3    Hao, F.4    Urba, W.J.5    Hu, H.M.6
  • 45
    • 81255138298 scopus 로고    scopus 로고
    • Tumor-derived autophagosome vaccine: Mechanism of cross-presentation and therapeutic efficacy
    • Li Y, Wang LX, Pang P et al. Tumor-derived autophagosome vaccine: Mechanism of cross-presentation and therapeutic efficacy. Clin. Cancer Res.17(22), 7047-7057 (2011
    • (2011) Clin. Cancer Res , vol.17 , Issue.22 , pp. 7047-7057
    • Li, Y.1    Wang, L.X.2    Pang, P.3
  • 46
    • 82455192402 scopus 로고    scopus 로고
    • DRiPs solidify: Progress in understanding endogenous MHC class I antigen processing
    • Yewdell JW. DRiPs solidify: Progress in understanding endogenous MHC class I antigen processing. Trends Immunol. 32(11), 548-558 (2011
    • (2011) Trends Immunol , vol.32 , Issue.11 , pp. 548-558
    • Yewdell, J.W.1
  • 47
    • 68049091014 scopus 로고    scopus 로고
    • Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17
    • Fransen JH, Hilbrands LB, Ruben J et al. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. Arthritis Rheum. 60(8), 2304-2313 (2009
    • (2009) Arthritis Rheum , vol.60 , Issue.8 , pp. 2304-2313
    • Fransen, J.H.1    Hilbrands, L.B.2    Ruben, J.3
  • 48
    • 0028091194 scopus 로고
    • A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
    • Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994
    • (1994) Nature , vol.367 , Issue.6464 , pp. 645-648
    • Lapidot, T.1    Sirard, C.2    Vormoor, J.3
  • 49
    • 0030789242 scopus 로고    scopus 로고
    • Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
    • Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730-737 (1997
    • (1997) Nat. Med , vol.3 , Issue.7 , pp. 730-737
    • Bonnet, D.1    Dick, J.E.2
  • 50
    • 33749436571 scopus 로고    scopus 로고
    • Searching for leukemia stem cells -not yet the end of the road?
    • Jordan CT. Searching for leukemia stem cells -not yet the end of the road? Cancer Cell 10(4), 253-254 (2006
    • (2006) Cancer Cell , vol.10 , Issue.4 , pp. 253-254
    • Jordan, C.T.1
  • 51
    • 58149380742 scopus 로고    scopus 로고
    • Stem cell concepts renew cancer research
    • Dick JE. Stem cell concepts renew cancer research. Blood 112(13), 4793-4807 (2008
    • (2008) Blood , vol.112 , Issue.13 , pp. 4793-4807
    • Dick, J.E.1
  • 52
    • 25144433295 scopus 로고    scopus 로고
    • High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
    • van Rhenen A, Feller N, Kelder A et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11(18), 6520-6527 (2005
    • (2005) Clin. Cancer Res , vol.11 , Issue.18 , pp. 6520-6527
    • Van Rhenen, A.1    Feller, N.2    Kelder, A.3
  • 53
    • 58049211689 scopus 로고    scopus 로고
    • Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia
    • Moshaver B, van Rhenen A, Kelder A et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 26(12), 3059-3067 (2008
    • (2008) Stem Cells , vol.26 , Issue.12 , pp. 3059-3067
    • Moshaver, B.1    Van Rhenen, A.2    Kelder, A.3
  • 54
    • 79955438869 scopus 로고    scopus 로고
    • SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes
    • Jeong HW, Cui W, Yang Y et al. SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PLoS ONE 6(4), e18372 (2011
    • (2011) PLoS ONE , vol.6 , Issue.4
    • Jeong, H.W.1    Cui, W.2    Yang, Y.3
  • 55
    • 0035883060 scopus 로고    scopus 로고
    • A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
    • Wulf GG, Wang RY, Kuehnle I et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98(4), 1166-1173 (2001
    • (2001) Blood , vol.98 , Issue.4 , pp. 1166-1173
    • Wulf, G.G.1    Wang, R.Y.2    Kuehnle, I.3
  • 56
    • 84859854912 scopus 로고    scopus 로고
    • A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia
    • Gerber JM, Smith BD, Ngwang B et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 119(15), 3571-3577 (2012
    • (2012) Blood , vol.119 , Issue.15 , pp. 3571-3577
    • Gerber, J.M.1    Smith, B.D.2    Ngwang, B.3
  • 57
    • 78649686241 scopus 로고    scopus 로고
    • TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells
    • Kikushige Y, Shima T, Takayanagi S et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7(6), 708-717 (2010
    • (2010) Cell Stem Cell , vol.7 , Issue.6 , pp. 708-717
    • Kikushige, Y.1    Shima, T.2    Takayanagi, S.3
  • 58
    • 34948839959 scopus 로고    scopus 로고
    • The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
    • van Rhenen A, van Dongen GA, Kelder A et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110(7), 2659-2666 (2007
    • (2007) Blood , vol.110 , Issue.7 , pp. 2659-2666
    • Van Rhenen, A.1    Van Dongen, G.A.2    Kelder, A.3
  • 59
    • 0033815950 scopus 로고    scopus 로고
    • The interleukin-3 receptor a chain is a unique marker for human acute myelogenous leukemia stem cells
    • Jordan CT, Upchurch D, Szilvassy SJ et al. The interleukin-3 receptor a chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14(10), 1777-1784 (2000
    • (2000) Leukemia , vol.14 , Issue.10 , pp. 1777-1784
    • Jordan, C.T.1    Upchurch, D.2    Szilvassy, S.J.3
  • 60
    • 34547415968 scopus 로고    scopus 로고
    • CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
    • Hosen N, Park CY, Tatsumi N et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl Acad. Sci. USA 104(26), 11008-11013 (2007
    • (2007) Proc. Natl Acad. Sci. USA , vol.104 , Issue.26 , pp. 11008-11013
    • Hosen, N.1    Park, C.Y.2    Tatsumi, N.3
  • 61
    • 84864255882 scopus 로고    scopus 로고
    • The origin and evolution of mutations in acute myeloid leukemia
    • Welch JS, Ley TJ, Link DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150(2), 264-278 (2012
    • (2012) Cell , vol.150 , Issue.2 , pp. 264-278
    • Welch, J.S.1    Ley, T.J.2    Link, D.C.3
  • 62
    • 84862776906 scopus 로고    scopus 로고
    • Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
    • Ding L, Ley TJ, Larson DE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382), 506-510 (2012
    • (2012) Nature , vol.481 , Issue.7382 , pp. 506-510
    • Ding, L.1    Ley, T.J.2    Larson, D.E.3
  • 63
    • 33748320471 scopus 로고    scopus 로고
    • New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents
    • Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology 2005(1), 143-150 (2005
    • (2005) Hematology , vol.2005 , Issue.1 , pp. 143-150
    • Tallman, M.S.1
  • 64
    • 84874403639 scopus 로고    scopus 로고
    • Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex
    • Gao C, Dimitrov T, Yong KJ et al. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood 121(8), 1413-1421 (2013
    • (2013) Blood , vol.121 , Issue.8 , pp. 1413-1421
    • Gao, C.1    Dimitrov, T.2    Yong, K.J.3
  • 65
    • 80053542413 scopus 로고    scopus 로고
    • Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells
    • Visus C, Wang Y, Lozano-Leon A et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. Clin. Cancer Res. 17(19), 6174-6184 (2011
    • (2011) Clin. Cancer Res , vol.17 , Issue.19 , pp. 6174-6184
    • Visus, C.1    Wang, Y.2    Lozano-Leon, A.3
  • 66
    • 80052468964 scopus 로고    scopus 로고
    • Stem cell gene expression programs influence clinical outcome in human leukemia
    • Eppert K, Takenaka K, Lechman ER et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17(9), 1086-1093 (2011
    • (2011) Nat. Med , vol.17 , Issue.9 , pp. 1086-1093
    • Eppert, K.1    Takenaka, K.2    Lechman, E.R.3
  • 67
    • 69849104865 scopus 로고    scopus 로고
    • The leukemic stem cell niche: Current concepts and therapeutic opportunities
    • Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: Current concepts and therapeutic opportunities. Blood 114(6), 1150-1157 (2009
    • (2009) Blood , vol.114 , Issue.6 , pp. 1150-1157
    • Lane, S.W.1    Scadden, D.T.2    Gilliland, D.G.3
  • 69
    • 35948984135 scopus 로고    scopus 로고
    • Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
    • Ishikawa F, Yoshida S, Saito Y et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25(11), 1315-1321 (2007
    • (2007) Nat. Biotechnol , vol.25 , Issue.11 , pp. 1315-1321
    • Ishikawa, F.1    Yoshida, S.2    Saito, Y.3
  • 70
    • 58249100053 scopus 로고    scopus 로고
    • CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers
    • Burger JA, Peled A. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia 23(1), 43-52 (2009
    • (2009) Leukemia , vol.23 , Issue.1 , pp. 43-52
    • Burger, J.A.1    Peled, A.2
  • 71
    • 84878411869 scopus 로고    scopus 로고
    • Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary co-cultures by altering the myeloid microenvironment
    • Schulz A, Dürr C, Zenz T et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary co-cultures by altering the myeloid microenvironment. Blood 121(13), 2503-2511 (2013
    • (2013) Blood , vol.121 , Issue.13 , pp. 2503-2511
    • Schulz, A.1    Dürr, C.2    Zenz, T.3
  • 72
    • 84876422526 scopus 로고    scopus 로고
    • Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence
    • Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23(3), 347-361 (2013
    • (2013) Cancer Cell , vol.23 , Issue.3 , pp. 347-361
    • Takeishi, S.1    Matsumoto, A.2    Onoyama, I.3    Naka, K.4    Hirao, A.5    Nakayama, K.I.6
  • 73
    • 0141461414 scopus 로고    scopus 로고
    • Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
    • Matsunaga T, Takemoto N, Sato T et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9(9), 1158-1165 (2003
    • (2003) Nat. Med , vol.9 , Issue.9 , pp. 1158-1165
    • Matsunaga, T.1    Takemoto, N.2    Sato, T.3
  • 74
    • 84868193304 scopus 로고    scopus 로고
    • A safety run-in and randomized Phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306
    • Nabors LB, Mikkelsen T, Hegi ME et al. A safety run-in and randomized Phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118(22), 5601-5607 (2012
    • (2012) Cancer , vol.118 , Issue.22 , pp. 5601-5607
    • Nabors, L.B.1    Mikkelsen, T.2    Hegi, M.E.3
  • 75
    • 79960898228 scopus 로고    scopus 로고
    • Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia
    • Shenghui Z, Yixiang H, Jianbo W et al. Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int. J. Cancer 129(6), 1373-1381 (2011
    • (2011) Int. J. Cancer , vol.129 , Issue.6 , pp. 1373-1381
    • Shenghui, Z.1    Yixiang, H.2    Jianbo, W.3
  • 76
    • 66149179122 scopus 로고    scopus 로고
    • Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia
    • Szczepanski MJ, Szajnik M, Czystowska M et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin. Cancer Res. 15(10), 3325-3332 (2009
    • (2009) Clin. Cancer Res , vol.15 , Issue.10 , pp. 3325-3332
    • Szczepanski, M.J.1    Szajnik, M.2    Czystowska, M.3
  • 77
    • 84873192230 scopus 로고    scopus 로고
    • Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia
    • Christiansson L, Söderlund S, Svensson E et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. PLoS ONE 8(1), e55818 (2013
    • (2013) PLoS ONE , vol.8 , Issue.1
    • Christiansson, L.1    Söderlund, S.2    Svensson, E.3
  • 78
    • 84875511757 scopus 로고    scopus 로고
    • Tumor necrosis factor-A blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation
    • Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-A blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38(3), 541-554 (2013
    • (2013) Immunity , vol.38 , Issue.3 , pp. 541-554
    • Sade-Feldman, M.1    Kanterman, J.2    Ish-Shalom, E.3    Elnekave, M.4    Horwitz, E.5    Baniyash, M.6
  • 79
    • 84863924314 scopus 로고    scopus 로고
    • Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective
    • Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective. Cancer Res. 72(14), 3439-3444 (2012
    • (2012) Cancer Res , vol.72 , Issue.14 , pp. 3439-3444
    • Le, D.T.1    Jaffee, E.M.2
  • 80
    • 77957723967 scopus 로고    scopus 로고
    • Upregulation of Tim-3 and PD 1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
    • Fourcade J, Sun Z, Benallaoua M et al. Upregulation of Tim-3 and PD 1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207(10), 2175-2186 (2010
    • (2010) J. Exp. Med , vol.207 , Issue.10 , pp. 2175-2186
    • Fourcade, J.1    Sun, Z.2    Benallaoua, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.